CASE STUDY 04

This case study examines the challenges of pharmaceutical procurement and regulatory harmonisation within the Southern African Development Community (SADC) region. It highlights how fragmented registration policies, weak regulatory capacity, and intellectual property barriers hinder access to essential medicines for treating HIV/AIDS, tuberculosis, malaria, and non-communicable diseases. The document emphasizes South Africa's pivotal role due to its advanced pharmaceutical sector and regulatory framework, while noting that political and economic interests often obstruct regional integration.

• Access to medicines in sub-Saharan Africa is hindered by small markets, inconsistent medicine registration policies across Southern Africa, and a shortage of quality control laboratories for testing generic medicines.
• The SADC region faces a high disease burden from HIV/AIDS, tuberculosis (TB), and malaria, alongside a rising prevalence of non-communicable diseases such as cancer, diabetes, and cardiovascular diseases among the middle class.
• Intellectual property laws, specifically the Trade Related Aspects of Intellectual Property Rights (TRIPS) agreement, create barriers to medicine affordability, although the Doha Declaration allows for compulsory licences and parallel imports.
• Efforts to harmonise medicine regulation in the region include the African Medicines Registration Harmonisation Initiative (launched February 2009) and the SADC Medicine Regulatory Authority Forum, though these attempts have not yet yielded significant results.
• Regional regulatory integration is obstructed by member states' reluctance to relinquish national sovereignty, fears that larger states will dominate the agenda, and concerns over potential job losses at national regulatory authorities.
• South Africa possesses the most advanced pharmaceutical sector in the SADC region, hosting approximately 40% of the region's 101 pharmaceutical manufacturers and serving as the only country capable of producing generic drugs.
• South Africa has the region's most advanced regulatory framework and is the furthest along in implementing TRIPS flexibilities, which allows the government to overrule certain intellectual property rights for national health benefits.
• The pharmaceutical industry, distributors, and pharmacies may lack incentive to support regional harmonisation because weak regulation allows them to source from preferred suppliers and set prices to their own advantage.

APA

South African Institute of International Affairs (n.d.). CASE STUDY 04. https://saiia.org.za/wp-content/uploads/2014/10/141125_EDIP_GIZreport_pg47-52_CS4.pdf

Chicago

South African Institute of International Affairs. CASE STUDY 04. n.d. https://saiia.org.za/wp-content/uploads/2014/10/141125_EDIP_GIZreport_pg47-52_CS4.pdf.

Wikipedia

{{cite report |author=South African Institute of International Affairs |title=CASE STUDY 04 |url=https://saiia.org.za/wp-content/uploads/2014/10/141125_EDIP_GIZreport_pg47-52_CS4.pdf |access-date=17 August 2026 |via=Climate Insights Directory}}

BibTeX

@techreport{southafricaninstituteofinternationalaffairsndcase, author = {{South African Institute of International Affairs}}, title = {{CASE STUDY 04}}, institution = {South African Institute of International Affairs}, url = {https://saiia.org.za/wp-content/uploads/2014/10/141125_EDIP_GIZreport_pg47-52_CS4.pdf}, urldate = {2026-08-17}, note = {Indexed by Climate Insights Directory} }